Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation.

Chen QF, Chen S, Jiang XY, Zhao M

Open source

DOI
10.1136/jitc-2025-012560
Published
2025 Aug 12
Container
Journal for immunotherapy of cancer
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2025-012560,
  title = {Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation.},
  author = {Chen QF and Chen S and Jiang XY and Zhao M},
  year = {2025},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2025-012560},
  url = {https://doi.org/10.1136/jitc-2025-012560}
}

RIS

TY  - JOUR
TI  - Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation.
AU  - Chen QF
AU  - Chen S
AU  - Jiang XY
AU  - Zhao M
PY  - 2025
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2025-012560
UR  - https://doi.org/10.1136/jitc-2025-012560
ER  - 

APA

QF, C., S, C., XY, J., & M, Z. (2025). Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2025-012560

Source records